Showing 2211-2220 of 7330 results for "".
Anti-Semitism and Dermatologists
https://practicaldermatology.com/series/editors-message/anti-semitism-and-dermatologists/23988/(A Personal Narrative from the Editor)Exploring Patient-Reported Outcomes Measures in Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/exploring-patient-reported-outcomes-measures-in-atopic-dermatitis/23886/Patient-reported outcomes may solve some of the challenges with measuring the physical and psychosocial manifestations.Strength in Numbers: Assessing Your Financial Position
https://practicaldermatology.com/topics/practice-management/strength-in-numbers-assessing-your-financial-position/23863/Look at your ratios and ranges to make sure you are keeping up with industry—and economic—shifts.Assessing the Pediatric Dermatology Workforce
https://practicaldermatology.com/topics/pediatric/assessing-the-pediatric-dermatology-workforce/23834/Physician Spotlight: Steven R. Feldman, MD, PhD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-4/23801/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-37/23755/New Products
https://practicaldermatology.com/columns/new-products/new-products-4/23753/The Best Skincare Products for Eczema, According to Your Peers
https://practicaldermatology.com/topics/atopic-dermatitis/the-best-skincare-products-for-eczema-according-to-your-peers/23747/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-36/23740/DermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility study